Test Price
3,000 AED✅ Home Collection Available
Breast Comprehensive Panel Genetic Test in UAE | 3,000 AED | 2026 DHA Guidelines
تحليل لوحة الثدي الشاملة باستخدام التسلسل الجيني من الجيل التالي (NGS) في الإمارات | 3,000 درهم | معتمد من هيئة الصحة بدبي
Clinical Executive Summary — الملخص التنفيذي السريري
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 accredited NGS processing with orthogonal variant confirmation. ضمان دقة تشخيصية بنسبة 99.9% عبر معالجة معتمدة بتقنية التسلسل الجيني المتقدم.
- ✓ Premium Logistics: Hospital-Grade Home Collection via ISO-Certified Cold-Chain transport — خدمة سحب الدم المنزلي بمعايير المستشفيات مع نقل مبرد معتمد دولياً.
- ✓ Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for result interpretation by a qualified genetic counsellor. استشارة هاتفية مجانية بعد الفحص لتفسير النتائج من قبل مستشار وراثي مؤهل.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. التحقق المباشر من تغطية التأمين عبر واتساب.
Comprehensive Overview
The Breast Comprehensive Panel Genetic Test is a clinically validated next-generation sequencing assay that simultaneously interrogates 30 high-penetrance hereditary cancer susceptibility genes — including BRCA1, BRCA2, TP53, PTEN, PALB2, ATM, CHEK2, CDH1, STK11, and others — to identify pathogenic germline variants associated with significantly elevated lifetime risk for breast, ovarian, pancreatic, and other syndromic malignancies. يُعد هذا الفحص الجيني الشامل أداة تشخيصية متقدمة لتحديد الطفرات الوراثية المرتبطة بارتفاع خطر الإصابة بسرطان الثدي والأورام الخبيثة المرتبطة به، مما يتيح اتخاذ قرارات سريرية استباقية قائمة على الأدلة.
This test is indicated for individuals with a personal or family history of early-onset breast cancer, bilateral breast cancer, triple-negative breast cancer, multiple primary cancers, or known familial pathogenic variants. It empowers patients and clinicians to pursue risk-reducing strategies, enhanced surveillance protocols, and targeted therapeutic interventions aligned with 2026 DHA precision medicine guidelines.
| Feature | Our Test — Breast Comprehensive NGS Panel | Closest Alternative — Single-Gene / BRCA1+2 Only |
|---|---|---|
| Genes Analyzed | 30 Genes (ABRAXAS1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2) | 2 Genes (BRCA1 + BRCA2 only) |
| Methodology | NGS with Full Exon & Splice-Site Coverage | 500x Mean Depth | GRCh38 Alignment | Sanger Sequencing or Limited PCR-Based Panels |
| Variant Classification | ACMG/AMP 2026 Guidelines with ClinVar, gnomAD v4, and dbNSFP annotations | ACMG 2015 Guidelines |
| Turnaround Time | 3 to 4 Weeks (Includes Confirmatory Orthogonal Validation) | 4 to 8 Weeks |
| Sample Types Accepted | Whole Blood (EDTA), Extracted DNA, or One-Drop Blood on FTA Card | Whole Blood Only |
| Price (UAE) | 3,000 AED | 1,500–2,500 AED |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy — DHA License No. 61713011 — Consultant Oncologist & Genomic Medicine Specialist
"In my two decades of clinical oncology practice across the UAE, I have witnessed how comprehensive multi-gene panel testing transforms patient outcomes. A negative BRCA-only test can provide false reassurance when a pathogenic PALB2 or TP53 variant is the true driver. This 30-gene panel closes those diagnostic gaps, enabling truly informed shared decision-making for prophylactic surgery, chemoprevention, or intensified surveillance. I urge every patient to review results in consultation with their treating oncologist or a certified genetic counsellor — a test result is a compass, not a destination."
⚠ Medication & Clinical Management Advisory
Do not discontinue any prescribed medication, hormone therapy, or surveillance regimen based solely on this genetic test result. Genetic findings must be interpreted within the full context of your personal medical history, family history, and current clinical status. Any modification to your treatment plan — including initiation of risk-reducing medications such as tamoxifen or raloxifene — must be undertaken only under direct supervision of your treating physician.
🚨 Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — This Test Is NOT Suitable For:
- Individuals under 18 years of age without court-authorised legal guardian consent (per UAE CDS Law 2026 — Minors).
- Patients seeking emergency diagnosis of an active, palpable breast mass or acute clinical symptoms.
- Somatic tumour profiling (this is a germline/heritable test only).
- Individuals who have not undergone or declined pre-test genetic counselling.
- Non-consenting individuals or those unable to provide informed consent per UAE PDPL requirements.
🚨 Seek Immediate Emergency Care If You Experience:
- A new, rapidly growing, or painful breast lump.
- Bloody or spontaneous nipple discharge.
- Skin dimpling, peau d'orange, or nipple retraction of recent onset.
- Unexplained axillary swelling or lymphadenopathy.
- Constitutional symptoms: unintentional weight loss, night sweats, or persistent bone pain.
Do not wait for genetic test results. These symptoms require immediate clinical evaluation, imaging (mammography/ultrasound), and possible biopsy.
Patient FAQ & Clinical Guidance
Q1: What exactly does the Breast Comprehensive Panel NGS test detect, and who should consider it?
The Breast Comprehensive Panel Genetic Test detects pathogenic, likely pathogenic, and variants of uncertain significance across 30 clinically actionable hereditary cancer genes — including BRCA1, BRCA2, TP53, PTEN, PALB2, ATM, CHEK2, CDH1, and STK11 — using high-depth next-generation sequencing with full exon and splice-site coverage aligned to the GRCh38 reference genome. This test is clinically indicated for individuals with a personal history of early-onset breast cancer (diagnosed before age 50), triple-negative breast cancer, bilateral breast cancer, ovarian cancer at any age, male breast cancer, or a strong family history of breast, ovarian, pancreatic, or aggressive prostate cancer across multiple generations. It is also recommended for individuals of Ashkenazi Jewish ancestry or those with a known familial pathogenic variant seeking cascade testing.
يكتشف اختبار لوحة الثدي الشاملة باستخدام التسلسل الجيني (NGS) الطفرات الجينية الممرضة والمحتملة الإمراض عبر 30 جيناً مرتبطاً بالسرطانات الوراثية القابلة للتدخل السريري، بما في ذلك BRCA1 وBRCA2 وTP53 وPTEN وPALB2 وATM وCHEK2 وCDH1 وSTK11. يُوصى بهذا الفحص للأفراد الذين لديهم تاريخ شخصي أو عائلي للإصابة بسرطان الثدي المبكر أو سرطان المبيض أو سرطان البنكرياس أو سرطان البروستاتا العدواني، وكذلك للأفراد المنحدرين من أصل يهودي أشكنازي أو الحاملين لطفرة عائلية معروفة.
Q2: How should I prepare for this test, and what does the pre-test genetic counselling involve?
Pre-test preparation requires a mandatory genetic counselling session — conducted by a DHA-licensed genetic counsellor — during which a detailed three-generation pedigree chart is constructed documenting all family members affected by cancers covered in the panel genes, including breast, ovarian, colorectal, endometrial, pancreatic, gastric, and thyroid malignancies, as well as ages at diagnosis and bilateral or multifocal disease patterns. No fasting or medication adjustments are required prior to sample collection; however, patients who have undergone allogeneic bone marrow transplantation should inform the laboratory as donor DNA may confound germline results. A clinical history form must be completed and submitted alongside the sample, detailing prior biopsies, hormone receptor status (if applicable), and any previous genetic testing results.
يتطلب التحضير لهذا الفحص جلسة استشارة وراثية إلزامية مع مستشار وراثي مرخص من هيئة الصحة بدبي، يتم خلالها رسم مخطط نسب عائلي مفصل لثلاثة أجيال يوثق جميع أفراد الأسرة المصابين بالسرطانات المشمولة في جينات اللوحة. لا يتطلب الفحص صياماً أو تعديلات دوائية، ولكن يجب على المرضى الذين خضعوا لزراعة نخاع عظمي خيفي إبلاغ المختبر مسبقاً.
Q3: What happens after I receive my results, and what do the different result categories mean?
Post-test results are classified according to the 2026 ACMG/AMP five-tier system: Pathogenic (Class 5), Likely Pathogenic (Class 4), Variant of Uncertain Significance — VUS (Class 3), Likely Benign (Class 2), and Benign (Class 1). A pathogenic or likely pathogenic finding triggers a structured post-test clinical guidance session wherein your referring oncologist or genetic counsellor outlines evidence-based risk management options, including enhanced breast MRI surveillance, risk-reducing mastectomy, chemoprevention with SERMs, or targeted screening for associated malignancies per NCCN and DHA 2026 guidelines. A VUS result is not clinically actionable and should not prompt prophylactic interventions; periodic reclassification monitoring is recommended as new population data emerge. All results are securely archived under UAE PDPL-compliant protocols, and cascade family testing can be arranged through our licensed network.
تُصنف النتائج وفقاً لنظام ACMG/AMP المكون من خمس فئات لعام 2026: ممرض (الفئة 5)، محتمل الإمراض (الفئة 4)، متغير غير مؤكد الأهمية (الفئة 3)، محتمل الحميدة (الفئة 2)، وحميد (الفئة 1). النتيجة الإيجابية تستدعي جلسة توجيه سريري بعد الفحص لمناقشة خيارات إدارة المخاطر القائمة على الأدلة، بما في ذلك التصوير بالرنين المغناطيسي المعزز والجراحة الوقائية والوقاية الكيميائية، وفقاً لإرشادات هيئة الصحة بدبي لعام 2026.
🎓 Pre- Information & Genetic Counselling Requirements
Prior to sample collection, all patients must undergo a comprehensive genetic counselling session to draw a detailed pedigree chart documenting family members affected with conditions linked to the following 30 genes:
These genes are associated with Hereditary Breast and Ovarian Cancer Syndrome, Li-Fraumeni Syndrome, Cowden Syndrome, Hereditary Diffuse Gastric Cancer Syndrome, Lynch Syndrome, Fanconi Anemia pathway disorders, and other hereditary cancer predisposition syndromes recognised under 2026 DHA oncology guidelines.
📦 Sample Collection & Logistics
- Accepted Sample Types: Whole Blood (EDTA tube, 4–6 mL), Extracted DNA (minimum 1 µg at ≥50 ng/µL, A260/A280: 1.8–2.0), or One-Drop Blood on FTA Card (fully dried, protected from contamination).
- Home Collection Service: VIP Mobile Phlebotomy available daily from 8:00 AM to 11:00 PM across all seven emirates. ISO-certified cold-chain transport ensures sample integrity from collection to laboratory accessioning.
- Turnaround Time: 3 to 4 Weeks from sample accessioning. Expedited processing available upon medical urgency request with referring physician authorisation.
- Facility License: DHA/MOHAP Facility No. 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
- Support & Booking: Call or WhatsApp +971 54 548 8731 for appointments, insurance verification, and clinical inquiries.
🔒 UAE Regulatory Compliance & Data Privacy Assurance
This service operates in full compliance with Federal Decree-Law No. 41 of 2024 (Article 87) governing clinical laboratory operations, UAE PDPL (Personal Data Protection Law) for genomic data privacy, and CDS Law 2026 regulations governing clinical decision support for minors. All patient genomic data is encrypted, pseudonymised, and stored within UAE-sovereign infrastructure. Cascade family testing and data-sharing requests require explicit written consent per UAE genetic privacy statutes.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians